TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23396375
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed generic formulation of S-1 (40 mg/m(2), po)
Study: 23396375
Drug: Branded reference
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded reference formulation of S-1 (40 mg/m(2), po)
Study: 23396375
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of S-1
Study: 19519724
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (8 mg/kg)
Study: 8794428
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement treatment (HRT) with transdermal 17 beta‐estradiol, 50 mg/day for 24 days/month and medroxiprogesterone, 10 mg for 12 days
Study: 8794428
Drug: Calcium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium treatment with elemental calcium, 1 g/day
Study: 8794428
Drug: Eel calcitonin
Normalized name: Calcitonin eel
DrugBank: Calcitonin eel (DB12898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eel calcitonin treatment with 40 IU/day for 10 days/month and elemental calcium, 500 mg/day
Study: 814955
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulphadiazine cream (SSD)
Study: 814955
Drug: 0.5% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% silver nitrate and 0.2% chlorhexidine digluconate cream (SNC)
Study: 26119844
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (1000 mg calcium daily plus 50000 IU vitamin D weekly)
Study: 26119844
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D alone (50000 IU weekly)
Study: 26119844
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium placebo daily plus vitamin D placebo weekly)
Study: 16785331
Drug: valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (80 to 160 mg)
Study: 15280154
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg orally four times daily)
Study: 3103761
Drug: Slow Sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Sodium tablets (100 mmol sodium chloride)
Study: 31268376
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg q2w + csDMARDs
Study: 31268376
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg q2w + csDMARDs
Study: 26603250
Drug: Non‐directive supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐directive supportive therapy (NDST)
Study: 18534136
Drug: Combination pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pharmacological cardioversion therapy with low‐dose oral amiodarone (2 mg/kg), captopril (0.25 mg/kg), and simvastatin (0.3 mg/kg) administered daily
Study: 12450897
Drug: 1 mmol
Normalized name: monobasic potassium phosphate 1 MMOL/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mmol glycine/kg lean body mass + 25 g glucose
Study: 10512559
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet intervention (group sessions weekly for 6 weeks, biweekly for 6 weeks, and monthly for 9 months)
Study: 8745134
Drug: Bupropion HCL
Normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion HCL (300 mg/day)
Study: 2029827
Drug: Allopurinol riboside,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol riboside, 25 mg/kg q.i.d. for 13 doses
Study: 28631923
Drug: Flavonoid-rich supplement
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich supplement (329 mg/d)
Study: 28631923
Drug: Flavonoid-rich supplement
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich supplement
Study: 24055998
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a week assessment of home spirometry and CF respiratory symptoms using an electronic device
Study: 21335941
Drug: Lidocaine suppository
Normalized name: lidocaine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine suppository (60 mg)
Study: 17471064
Drug: Sham analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham analgesic cream
Study: 17471064
Drug: Inactive cream
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive cream
Study: 17471064
Drug: Inactive cream
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive cream (control)
Study: 15190832
Drug: Biological organic
Normalized name: Organix Complete
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological organic zinc after routine antibiotic treatment
Study: 15190832
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic treatment only
Study: 2504265
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 50 micrograms
Study: 31344296
Drug: HPC-NL +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPC-NL + B (10 mg/daily)
Study: 26167637
Drug: Early high-volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-volume hemofiltration (HVHF) at 80 ml/kg/h for 48 hours
Study: 24011983
Drug: Functional abilities
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional abilities in activities of daily living
Study: 20434290
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment intensification (TI)
Study: 15872238
Drug: Valacyclovir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (2 g twice on the day of treatment and 1 g twice the following day)
Study: 12517199
Drug: Nebulizer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer group (received nebulized albuterol)
Study: 12517199
Drug: Spacer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spacer group (received albuterol by metered-dose inhaler with a spacer)
Study: 8867518
Drug: Apomorphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine infusion (low, medium, high rates)
Study: 6200724
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine bolus (0.15 mg/kg)
Study: 6200724
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isosorbide dinitrate and hydralazine
Study: 26474989
Drug: S-1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 and oxaliplatin (SOX) therapy
Study: 26474989
Drug: S-1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 and cisplatin (CS) therapy
Study: 22893765
Drug: Low-intensity stretching
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity stretching control treatment (n = 16)
Study: 19094450
Drug: Intravenous supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous supplementation with glutamine dipeptide (Gln) 30 g/day
Study: 19094450
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid mixture (control) 25 g/day
Study: 29509892
Drug: Conventional chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional chest tube treatment
Study: 19803312
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg of intravenous fentanyl
Study: 15735462
Drug: 5.25% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% sodium hypochlorite with 17% EDTA for 1 min followed by 5-ml rinse with 5.25% NaOCl
Study: 12895193
Drug: Quinidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (3 mg kg(‐1))
Study: 6383760
Drug: Placebo (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initial single infusion)
Study: 31389509
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine injection (0.375% at doses of 2.5 ml in each belly of the anterior and middle scalene muscles, guided by ultrasonography)
Study: 27757595
Drug: Soy nutritional
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy nutritional intervention (30 g/day soy protein)
Study: 25277170
Drug: Resection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection of the primary tumour followed by systemic therapy (fluoropyrimidine-based chemotherapy in combination with bevacizumab)
Study: 25277170
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy only (fluoropyrimidine-based chemotherapy in combination with bevacizumab)
Study: 20175609
Drug: Family focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family focused treatment
Study: 15734713
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity treatment designed to increase TEE by 7%
Study: 15734713
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity treatment designed to increase TEE by 11%
Study: 10433672
Drug: Alcohol gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol gel sanitizer with antimicrobial lotion soap
Study: 10433672
Drug: Alcohol gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol gel sanitizer with nonantimicrobial lotion soap
Study: 10433672
Drug: Alcohol gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol gel sanitizer alone
Study: 10433672
Drug: Antimicrobial lotion
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial lotion soap alone
Study: 10433672
Drug: Nonantimicrobial lotion
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonantimicrobial lotion soap alone
Study: 215555
Drug: Erythromycin (40-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (40-50 mg/kg/day)
Study: 215555
Drug: Amoxycillin (25-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (25-30 mg/kg/day)
Study: 215555
Drug: Erythromycin (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (lower dosage)
Study: 31439593
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (2 mg naloxone, max 8 mg/day)
Study: 31439593
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (4 mg naloxone, max 16 mg/day)
Study: 24428092
Drug: 10% onion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% onion extract in silicone derivative gel
Study: 18038502
Drug: Vitaphenol Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitaphenol Skin Cream (La Jolla Spa MD, La Jolla CA) applied to half of the face twice daily for 60 days
Study: 18038502
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to half of the face twice daily for 60 days
Study: 18038502
Drug: Vitaphenol Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitaphenol Skin Cream
Study: 14742357
Drug: Low-molecular-weight HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight HES (HES 120; 20 mL/kg)
Study: 14742357
Drug: High-molecular-weight HES
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-molecular-weight HES (HES 400; 20 mL/kg)
Study: 1821972
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of clomipramine at doses 75-300 mg daily for 7 to 16 days
Study: 1821972
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of maprotiline at doses 75-200 mg daily for 6 to 20 days
Study: 7032378
Drug: 32 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg/d methylprednisolone
Study: 7032378
Drug: Inhaled beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta agonists
Study: 30235727
Drug: Hanslim (high-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hanslim (high-dose)
Study: 30235727
Drug: Hanslim (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hanslim (low-dose)
Study: 20851055
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT), delivered via Internet or telephone, 8 sessions over 8 weeks
Study: 8664221
Drug: Oestradiol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (5 mg/100 g)
Study: 26920606
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus cilostazol therapy
Study: 20171665
Drug: Acitretin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (35 mg daily for 20 weeks)
Study: 16814823
Drug: Single-dose tafenoquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose tafenoquine (400mg daily x 3 days)
Study: 16814823
Drug: Split-dose tafenoquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose tafenoquine (200 mg twice daily x 3 days)
Study: 15823102
Drug: Primary debulking
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary debulking surgery followed by platinum-based chemotherapy
Study: 9615912
Drug: Pravastatin (Pravachol),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (Pravachol), 20 mg twice daily for 12, 24, 48 and 72 hours preoperatively
Study: 3683021
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 1000 mg
Study: 30259621
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) plus Pioglitazone (30 mg)
Study: 30259621
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) alone
Study: 25795524
Drug: Affect Labeling
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affect Labeling during exposure therapy
Study: 18786258
Drug: Belimumab (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (1.0, 4.0, 10, and 20 mg/kg)
Study: 18786258
Drug: Belimumab (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (two doses)
Study: 10369424
Drug: Repaglinide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.5 mg three times/day preprandially, adjusted to 1, 2 or 4 mg)
Study: 10369424
Drug: Glyburide (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (starting dose of 2.5 mg before breakfast, adjusted to 5 or 10 mg)
Study: 7537355
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.25 U/kg/week)
Study: 27263034
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard statin therapy)
Study: 20381657
Drug: Evidence-based antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based antiplatelet and antithrombin therapies during the initial 24 hours of hospital admission
Study: 15523399
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch 25 mg per day
Study: 11122841
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy plus radiotherapy
Study: 11122841
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy followed by radiation therapy (combined modality therapy)
Study: 27100726
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (1 gram in two divided doses)
Study: 18339258
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (IMP) 50 mg daily
Study: 18339258
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal gel (VGP) 90 mg once daily
Study: 18339258
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal gel (VGP) 90 mg twice daily
Study: 12869088
Drug: Quinine dihydrochloride
Normalized name: quinine dihydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine dihydrochloride (Qn) with pentoxifylline (Px) (10 mg/kg/day for 3 days)
Study: 2861527
Drug: Triamterene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (50 mg/day)
Study: 2861527
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg/day)
Study: 2861527
Drug: Triamterene-containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene-containing combination diuretic
Study: 29193093
Drug: Daily breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily breakfast consumption (BFAST; ≥700 kcal before 11.00 h)
Study: 23656841
Drug: Levomilnacipran SR
Normalized name: Levomilnacipran
DrugBank: Levomilnacipran (DB08918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levomilnacipran SR (75 mg or 100 mg)
Study: 19356393
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release cyclobenzaprine tablet (20 mg)
Study: 19356393
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release cyclobenzaprine tablet (20 mg) with high fat meal
Study: 19356393
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release cyclobenzaprine tablet (10 mg)
Study: 17239355
Drug: D-amphetamine 10
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine 10 mg
Study: 9039834
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (30 mg betaC/d)
Study: 8174049
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg etidronate disodium for 24 hours
Study: 8174049
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg etidronate disodium for 24 hours
Study: 29540217
Drug: Linagliptin once
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin once daily
Study: 26439936
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of iodopovidone
Study: 2511911
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg twice daily plus Atenolol 50 mg twice daily
Study: 2511911
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg twice daily plus Atenolol 50 mg twice daily
Study: 12618533
Drug: Low-dose ACTH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACTH
Study: 29908688
Drug: Honey (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey (70 g per day)
Study: 29908688
Drug: Sucrose (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (70 g per day)
Study: 27703294
Drug: Lisinopril/Hydrochlorothiazide
Normalized name: lisinopril/hydrochlorothiazide 20 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/Hydrochlorothiazide
Study: 24779731
Drug: Two drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two drug combinations
Study: 21029610
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid orally
Study: 21029610
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + tibolone 1.25 mg/d orally
Study: 21029610
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + bisphosphonates 70 mg/w orally
Study: 15960573
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase dosing of escitalopram (10-20 mg/day)
Study: 15960573
Drug: Symptom-onset dosing
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-onset dosing of escitalopram (10-20 mg/day)
Study: 10596559
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (0.15 mg infusion 15 minutes before operation)
Study: 10596559
Drug: Intramuscular clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular clonidine (0.15 mg 60-90 minutes before operation)
Study: 1781761
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate cream 0.05% applied twice daily
Study: 29577512
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy (CRT) in addition to standard treatment